RxDoctor Payments Data

Christopher Donovan, MD

Ophthalmology · Brandon, FLNPI 1770945982

Payments from drug & device makers

$6,245in general payments, 2019–2025

Across 162 payments — averaging $38.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$942
  • Alcon$783
  • Mallinckrodt Hospital Products Inc.$652
  • Amgen$456
  • Dompe US, Inc.$435
  • AbbVie$425
  • plus $3K from 15 others

What the payments were for

  • Food & beverage$6,245100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,245 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$251,976
Medicare patients
514
Services billed
1,909

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf120$98,104
XiidraLifitegrast14$23,949
Prednisolone Acetate420$23,022
CequaCyclosporine15$16,128
RestasisCyclosporine14$11,520
MoxifloxacinMoxifloxacin Hcl300$9,209
VyzultaLatanoprostene Bunod14$7,249
SimbrinzaBrinzolamide/Brimonidine Tart30$6,038
RocklatanNetarsudil Mesylat/Latanoprost11$3,616
Loteprednol Etabonate21$3,343
ValacyclovirValacyclovir Hcl49$2,496
Ketorolac Tromethamine49$1,805
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,477
ErythromycinErythromycin Base75$801
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta$402$129,302148 claims
Sun Pharmaceutical Industries Inc.Cequa$107$16,12815 claims
AbbVieRestasis$425$11,52014 claims
AlconSimbrinza$783$6,03830 claims
Aerie Pharmaceuticals, Inc.Rocklatan$120$3,61611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →